{"nctId":"NCT01765179","briefTitle":"Safety and Efficacy Trial of Testosterone Undecanoate","startDateStruct":{"date":"2013-01"},"conditions":["Male Hypogonadism"],"count":144,"armGroups":[{"label":"Oral testosterone undecanoate","type":"EXPERIMENTAL","interventionNames":["Drug: Oral testosterone undecanoate"]}],"interventions":[{"name":"Oral testosterone undecanoate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Serum testosterone of less than or equal to 300 ng/dL (the mean of two samples collected 1 hour apart in the morning between 6:00 and 10:00 AM)\n\nExclusion Criteria:\n\n* Significant intercurrent disease of any type, in particular liver, kidney, uncontrolled or poorly controlled heart disease including hypertension, CHF or CAD, or psychiatric illness including depression.\n* Recent history of stroke, including transient ischemic attack (TIA) or acute coronary event\n* Untreated, severe obstructive sleep apnea\n* Hematocrit \\<35% or \\>48%\n* Serum transaminases \\>2 times upper limit of normal, serum bilirubin \\>2.0 mg/dL, and serum creatinine \\>2.0 mg/dL\n* BMI \\> or equal to 38\n* Stable doses of lipid-lowering medication for less than three months\n* Stable doses of oral medication for diabetes for less than two months\n* Abnormal prostate digital rectal examination \\[palpable nodule(s)\\], elevated PSA (serum PSA \\>3.9 ng/mL), IPSS score \\> or equal to 19 points, and /or history of prostate cancer.\n* History of breast cancer\n* Use of dietary supplement saw palmetto or phytoestrogens and use of any dietary supplements that may increase serum T, such as androstenedione or DHEA with the previous 4 weeks\n* Know malabsorption syndrome and/or current treatment iwht oral lipase inhibitors\n* Known history of abuse of alcohol or any drug substance with the previous 2 years\n* Current use of antiandrogens, estrogens, oral CYP3A4 inducers or inhibitors, or long-acting opioid analgesics\n* Receipt of any drug as part of a research study within 30 days of initial dose administration in this study\n* Blood donation within the 12 week period before initial dose administration in this study","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Treated Patients With an Average Serum Testosterone (T) Concentration (Cavg) Between 300 and 1000 ng/dL","description":"The number of subjects (116) analyzed includes only those subjects with serum testosterone Cavg data available on study day 114.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Treated Patients With Maximum Serum T Concentrations (Cmax) Values in Selected Ranges on Day 114 Efficacy Population","description":"The number of subjects (116) analyzed includes only those subjects with serum testosterone Cavg data available on study day 114.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":144},"commonTop":["diarrhea","upper respiratory tract infection","dyspepsia","oedema peripheral","hypertension"]}}}